Evidence map›Paper›PMID 39106307›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Development of a highly sensitive platform for protein-protein interaction detection and regulation of T cell function.

Hideki Hayashi, Tak Wah Mak, Yoshimasa Tanaka, Yoshinao Kubo, Mai Izumida, Ryuji Urae, Toshifumi Matsuyama

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Host Responses to SARS-CoV-2 with an Emphasis on Cytokines.International journal of molecular sciences · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hideki HayashiMedical University Research Administrator, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan.ORCID 0000-0003-4585-6542
Tak Wah MakCenter for Medical Innovation, Nagasaki University, Nagasaki 852-8588, Japan.ORCID 0000-0001-6766-861X
Yoshimasa TanakaCentre for Oncology and Immunology, Hong Kong Science Park, Hong Kong Special Administrative Region 999077, China.
Yoshinao KuboDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.
Mai IzumidaDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.
Ryuji UraeSouseikai Clinical Research Center, Fukuoka 812-0025, Japan.
Toshifumi MatsuyamaDepartment of Forensic Pathology and Science, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We developed a highly sensitive assay for detecting protein-protein interaction using chimeric receptors comprising two molecules of interest in the extracellular domain and interferon alpha and beta receptor subunit 1 or 2 (IFNAR1/2) in the intracellular domain. This intracellular IFNAR1/2 reconstitution system (IFNARRS) proved markedly more sensitive than the NanoBiT system, currently considered one of the best detection systems for protein interaction. Employing chimeric receptors with extracellular domains from the IFNγ or IL-2 receptor and the intracellular domains of IFNAR1/2, the IFNARRS system effectively identifies low IFNγ or IL-2 levels. Cells stably expressing these chimeric receptors responded to IFNγ secreted by activated T cells following various stimuli, including a specific peptide-antigen. The activation signals were further enhanced by the expression of relevant genes, such as costimulators, via IFN-stimulated response elements in the promoters. Besides IFNγ or IL-2, the IFNARRS system demonstrated the capability to detect other cytokines by using the corresponding extracellular domains from these target cytokine receptors.

Indexed as

Interferon-gammaInterleukin-2Receptor, Interferon alpha-betaT-LymphocytesHEK293 CellsHumansLymphocyte ActivationProtein BindingReceptors, Interleukin-2IFNAR1 protein, humanIFNAR2 protein, humanInterferon-gammaInterleukin-2Receptor, Interferon alpha-betaReceptors, Interleukin-2IL-2interferon-gammainterferon signalingprotein interactionT cell activation

Identifiers

PMID39106307
PMCPMC11331103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.